Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel ...
Ipsen has entered an exclusive global licensing agreement with Foreseen Biotechnology for FS001, a potentially first-in-class antibody-drug conjugate (ADC). This partnership grants Ipsen worldwide ...
Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bio. Under ...
Ipsen and Foreseen Biotechnology have entered into an exclusive global licensing agreement worth up to $1.03bn for a preclinical antibody-drug conjugate (ADC). The deal gives Ipsen exclusive worldwide ...
These days, a whole lot of really great bands have been exploring the sound of late-'80s crossover thrash -- the moment where the hardcore and metal undergrounds sort of put their heads down, charged ...
Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results